At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
SQIN-01combination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single Dose Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure: a Phase I Clinical Trial
In Brief
A Phase 1 clinical trial evaluating SQIN-01 for Heart Failure. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a single-centre, prospective, open-label, non-comparative clinical trial assessing the on-body performance of an investigational drug delivery device (SQIN-Infusor) in patients hospitalised due to HF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited Kingdom
CollaboratorsUniversity of Glasgow, NHS Greater Glasgow and Clyde
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionAug 2021
TodayJul 2026
First PostedApr 15, 2021
Enrollment StartMay 6, 2021
Primary CompletionAug 13, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.2 years ago
Interventions
SQIN-01combination
The drug and device combination is called SQIN-01. SQIN-01 is a combination of SQIN-Infusor and SQIN-Furosemide Investigational pump (SQIN-Infusor, medical device) intended for subcutaneous infusion of investigational product, SQINFurosemide.